BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, Gebhart JH, Tylicki AE, Shoyoye SO, Martin CF, Galanko JA, Baron JA, Shaheen NJ. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial. Gastroenterology. 2019;157:65-73.e5. [PMID: 30872104 DOI: 10.1053/j.gastro.2019.03.014] [Cited by in Crossref: 37] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Liu X, Xiao X, Liu D, Tan C. A meta-analysis on randomized controlled trials of treating eosinophilic esophagitis with budesonide. Ann Med 2022;54:2078-88. [PMID: 35862288 DOI: 10.1080/07853890.2022.2101689] [Reference Citation Analysis]
2 Lucendo AJ, Molina-Infante J. Current treatment options and long-term outcomes in patients with eosinophilic esophagitis. Expert Rev Clin Immunol 2022;:1-14. [PMID: 35770955 DOI: 10.1080/1744666X.2022.2096591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Schupack DA, Johnson K, Akambase JA, Geno D, Lavey C, Lennon RJ, Ravi K, Snyder DL, Katzka DA, Alexander JA. Histologic response to steroids in eosinophilic esophagitis is dependent on delivery compound. Dis Esophagus 2022:doac040. [PMID: 35780320 DOI: 10.1093/dote/doac040] [Reference Citation Analysis]
4 Strauss AL, Falk GW. Refractory eosinophilic esophagitis: what to do when the patient has not responded to proton pump inhibitors, steroids and diet. Curr Opin Gastroenterol 2022;38:395-401. [PMID: 35762699 DOI: 10.1097/MOG.0000000000000842] [Reference Citation Analysis]
5 Dhar A, Haboubi HN, Attwood SE, Auth MKH, Dunn JM, Sweis R, Morris D, Epstein J, Novelli MR, Hunter H, Cordell A, Hall S, Hayat JO, Kapur K, Moore AR, Read C, Sami SS, Turner PJ, Trudgill NJ. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut 2022:gutjnl-2022-327326. [PMID: 35606089 DOI: 10.1136/gutjnl-2022-327326] [Reference Citation Analysis]
6 Dellon ES, Khoury P, Muir AB, Liacouras CA, Safroneeva E, Atkins D, Collins MH, Gonsalves N, Falk GW, Spergel JM, Hirano I, Chehade M, Schoepfer AM, Menard-Katcher C, Katzka DA, Bonis PA, Bredenoord AJ, Geng B, Jensen ET, Pesek RD, Feuerstadt P, Gupta SK, Lucendo AJ, Genta RM, Hiremath G, McGowan EC, Moawad FJ, Peterson KA, Rothenberg ME, Straumann A, Furuta GT, Aceves SS. A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Gastroenterology 2022:S0016-5085(22)00287-6. [PMID: 35606197 DOI: 10.1053/j.gastro.2022.03.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sher ER, Ross JA, Weine DM, Chandini Arjun A. Current and emerging therapies for eosinophilic esophagitis. Allergy Asthma Proc 2022;43:178-86. [PMID: 35524356 DOI: 10.2500/aap.2022.43.220014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dellon ES, Khoury P, Muir AB, Liacouras CA, Safroneeva E, Atkins D, Collins MH, Gonsalves N, Falk GW, Spergel JM, Hirano I, Chehade M, Schoepfer AM, Menard-katcher C, Katzka DA, Bonis PA, Bredenoord AJ, Geng B, Jensen ET, Pesek RD, Feuerstadt P, Gupta SK, Lucendo AJ, Genta RM, Hiremath G, Mcgowan EC, Moawad FJ, Peterson KA, Rothenberg ME, Straumann A, Furuta GT, Aceves SS. A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Journal of Allergy and Clinical Immunology 2022. [DOI: 10.1016/j.jaci.2022.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Marabotto E, Giannini EG, Zentilin P, Ziola S, Djahandideh Sheijani A, Savarino E, Savarino V. Pharmacotherapies in eosinophilic esophagitis: state of the art. Minerva Gastroenterol (Torino) 2022;68:69-76. [PMID: 35302339 DOI: 10.23736/S2724-5985.21.02781-1] [Reference Citation Analysis]
10 Główczewski A, Krogulska A. Formulations of Topical Steroids in Eosinophilic Esophagitis-Current Treatment and Emerging Possibilities. J Clin Med 2022;11:1454. [PMID: 35268544 DOI: 10.3390/jcm11051454] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Young E, Philpott H. Pathophysiology of Dysphagia in Eosinophilic Esophagitis: Causes, Consequences, and Management. Dig Dis Sci 2022. [PMID: 35230577 DOI: 10.1007/s10620-022-07419-6] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Krause J, Brokmann F, Rosenbaum C, Weitschies W. The challenges of drug delivery to the esophagus and how to overcome them. Expert Opinion on Drug Delivery. [DOI: 10.1080/17425247.2022.2033206] [Reference Citation Analysis]
13 Feo-ortega S, Lucendo AJ. Evidence-based treatments for eosinophilic esophagitis: insights for the clinician. Therap Adv Gastroenterol 2022;15:175628482110686. [DOI: 10.1177/17562848211068665] [Reference Citation Analysis]
14 Dorsey YC, Song EJ, Leiman DA. Beyond the Eckardt Score: Patient-Reported Outcomes Measures in Esophageal Disorders. Curr Gastroenterol Rep 2021;23:29. [PMID: 34850300 DOI: 10.1007/s11894-021-00831-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Chu JN, Traverso G. Foundations of gastrointestinal-based drug delivery and future developments. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34785786 DOI: 10.1038/s41575-021-00539-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Ketchem CJ, Thakkar KP, Xue A, Reddy S, Abramson L, Greenberg SB, Abichandani S, Miller TL, Chang NC, Eluri S, Reed CC, Dellon ES. Older patients with eosinophilic esophagitis have high treatment response to topical steroids. Dig Liver Dis 2021:S1590-8658(21)00809-4. [PMID: 34789398 DOI: 10.1016/j.dld.2021.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ruffner MA, Juste L, Muir AB. Medical Management of Eosinophilic Esophagitis in Pediatric Patients. Pediatr Clin North Am 2021;68:1191-204. [PMID: 34736584 DOI: 10.1016/j.pcl.2021.07.014] [Reference Citation Analysis]
18 Fernandez-Becker NQ. Eosinophilic Esophagitis: Incidence, Diagnosis, Management, and Future Directions. Gastroenterol Clin North Am 2021;50:825-41. [PMID: 34717873 DOI: 10.1016/j.gtc.2021.08.001] [Reference Citation Analysis]
19 Muir A, Falk GW. Eosinophilic Esophagitis: A Review. JAMA 2021;326:1310-8. [PMID: 34609446 DOI: 10.1001/jama.2021.14920] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Chehade M, Aceves SS. Treatment of Eosinophilic Esophagitis: Diet or Medication? The Journal of Allergy and Clinical Immunology: In Practice 2021;9:3249-56. [DOI: 10.1016/j.jaip.2021.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Ketchem CJ, Reed CC, Stefanadis Z, Dellon ES. Treatment with compounded fluticasone suspension improves the clinical, endoscopic, and histologic features of eosinophilic esophagitis. Dis Esophagus 2021;34:doaa120. [PMID: 33306783 DOI: 10.1093/dote/doaa120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Nistel M, Nguyen N, Atkins D, Miyazawa H, Burger C, Furuta GT, Menard-Katcher C. Ciclesonide Impacts Clinicopathological Features of Eosinophilic Esophagitis. J Allergy Clin Immunol Pract 2021:S2213-2198(21)00792-3. [PMID: 34293498 DOI: 10.1016/j.jaip.2021.06.058] [Reference Citation Analysis]
23 Dellon ES, Woosley JT, McGee SJ, Moist SE, Shaheen NJ. Utility of major basic protein, eotaxin-3, and mast cell tryptase staining for prediction of response to topical steroid treatment in eosinophilic esophagitis: analysis of a randomized, double-blind, double dummy clinical trial. Dis Esophagus 2020;33:doaa003. [PMID: 32193541 DOI: 10.1093/dote/doaa003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Ma C, Schoepfer AM, Dellon ES, Bredenoord AJ, Chehade M, Collins MH, Feagan BG, Furuta GT, Gupta SK, Hirano I, Jairath V, Katzka DA, Pai RK, Rothenberg ME, Straumann A, Aceves SS, Alexander JA, Arva NC, Atkins D, Biedermann L, Blanchard C, Cianferoni A, Ciriza de Los Rios C, Clayton F, Davis CM, de Bortoli N, Dias JA, Falk GW, Genta RM, Ghaffari G, Gonsalves N, Greuter T, Hopp R, Hsu Blatman KS, Jensen ET, Johnston D, Kagalwalla AF, Larsson HM, Leung J, Louis H, Masterson JC, Menard-Katcher C, Menard-Katcher PA, Moawad FJ, Muir AB, Mukkada VA, Penagini R, Pesek RD, Peterson K, Putnam PE, Ravelli A, Savarino EV, Schlag C, Schreiner P, Simon D, Smyrk TC, Spergel JM, Taft TH, Terreehorst I, Vanuytsel T, Venter C, Vieira MC, Vieth M, Vlieg-Boerstra B, von Arnim U, Walker MM, Wechsler JB, Woodland P, Woosley JT, Yang GY, Zevit N, Safroneeva E; COREOS Collaborators:. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol 2021:S0091-6749(21)01059-9. [PMID: 34242635 DOI: 10.1016/j.jaci.2021.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
25 Tytor J, Larsson H, Bove M, Johansson L, Bergquist H. Topically applied mometasone furoate improves dysphagia in adult eosinophilic esophagitis - results from a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2021;56:629-34. [PMID: 33831327 DOI: 10.1080/00365521.2021.1906314] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
26 Mehta P, Pan Z, Skirka S, Kwan BM, Menard-Katcher C. Medication Adherence Aligns with Age and a Behavioral Checklist but Not Symptoms or Quality of Life for Patients with Eosinophilic Esophagitis. J Pediatr 2021;235:246-252.e1. [PMID: 33811869 DOI: 10.1016/j.jpeds.2021.03.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Prasher A, Shrivastava R, Dahl D, Sharma-Huynh P, Maturavongsadit P, Pridgen T, Schorzman A, Zamboni W, Ban J, Blikslager A, Dellon ES, Benhabbour SR. Steroid Eluting Esophageal-Targeted Drug Delivery Devices for Treatment of Eosinophilic Esophagitis. Polymers (Basel) 2021;13:557. [PMID: 33668571 DOI: 10.3390/polym13040557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Visaggi P, Savarino E, Sciume G, Chio TD, Bronzini F, Tolone S, Frazzoni M, Pugno C, Ghisa M, Bertani L, Bellini M, Savarino V, Peroni D, Marchi S, de Bortoli N. Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. Therap Adv Gastroenterol 2021;14:1756284820980860. [PMID: 33613690 DOI: 10.1177/1756284820980860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
29 Ayaki M, Manabe N, Fujita M, Nakamura J, Sunago A, Kamada T, Haruma K. A case of eosinophilic esophagitis with autoimmune polyendocrine syndrome type 2, including autoimmune gastritis. Clin J Gastroenterol 2021;14:460-5. [PMID: 33411318 DOI: 10.1007/s12328-020-01333-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Safroneeva E, Cotton CC, Schoepfer AM, Zwahlen M, Woosley JT, Dellon ES. Dilation Modifies Association Between Symptoms and Esophageal Eosinophilia in Adult Patients With Eosinophilic Esophagitis. Am J Gastroenterol 2020;115:2098-102. [PMID: 33009060 DOI: 10.14309/ajg.0000000000000957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
31 Dellon ES. Red Between the Lines: Evolution of Eosinophilic Esophagitis as a Distinct Clinicopathologic Syndrome. Dig Dis Sci 2020;65:3434-47. [PMID: 33052498 DOI: 10.1007/s10620-020-06642-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Eluri S, Corder SR, Kim E, Tappata M, Reed CC, Shaheen NJ, Dellon ES. Clinical features and time trends associated with an endoscopically normal esophagus in active eosinophilic esophagitis. Endoscopy 2021;53:886-92. [DOI: 10.1055/a-1284-5891] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
33 Syverson EP, Hait EJ. Treatment for eosinophilic esophagitis. Curr Opin Gastroenterol 2020;36:485-90. [PMID: 33009017 DOI: 10.1097/MOG.0000000000000681] [Reference Citation Analysis]
34 Nennstiel S, Schlag C. Treatment of eosinophlic esophagitis with swallowed topical corticosteroids. World J Gastroenterol 2020; 26(36): 5395-5407 [PMID: 33024392 DOI: 10.3748/wjg.v26.i36.5395] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Greuter T, Godat A, Ringel A, Almonte HS, Schupack D, Mendoza G, McCright-Gill T, Dellon ES, Hirano I, Alexander J, Chehade M, Safroneeva E, Bussmann C, Biedermann L, Schreiner P, Schoepfer AM, Straumann A, Katzka DA. Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31136-8. [PMID: 32798703 DOI: 10.1016/j.cgh.2020.08.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
36 Fernandez-Becker NQ, Raja S, Scarpignato C, Lynch KL, Ahuja NK, Horsley-Silva JL. Eosinophilic esophagitis: updates on key unanswered questions. Ann N Y Acad Sci 2020;1481:30-42. [PMID: 32762154 DOI: 10.1111/nyas.14421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Straumann A, Lucendo AJ, Miehlke S, Vieth M, Schlag C, Biedermann L, Vaquero CS, Ciriza de Los Rios C, Schmoecker C, Madisch A, Hruz P, Hayat J, von Arnim U, Bredenoord AJ, Schubert S, Mueller R, Greinwald R, Schoepfer A, Attwood S; International EOS-2 Study Group. Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis. Gastroenterology 2020;159:1672-1685.e5. [PMID: 32721437 DOI: 10.1053/j.gastro.2020.07.039] [Cited by in Crossref: 16] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
38 Reddy A, Ashat D, Murali AR. Recent insights on the use of topical steroids in eosinophilic esophagitis. Expert Rev Gastroenterol Hepatol 2020;14:953-63. [PMID: 32567417 DOI: 10.1080/17474124.2020.1785869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
39 Rossetti D, Isoldi S, Oliva S. Eosinophilic Esophagitis: Update on Diagnosis and Treatment in Pediatric Patients. Paediatr Drugs 2020;22:343-56. [PMID: 32519266 DOI: 10.1007/s40272-020-00398-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
40 Miehlke S, Lucendo AJ, Straumann A, Jan Bredenoord A, Attwood S. Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. Therap Adv Gastroenterol 2020;13:1756284820927282. [PMID: 32565912 DOI: 10.1177/1756284820927282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
41 Slack IF, Schwartz JT, Mukkada VA, Hottinger S, Abonia JP. Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine. Curr Allergy Asthma Rep 2020;20:30. [PMID: 32506181 DOI: 10.1007/s11882-020-00928-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Ananthakrishnan A. Issue Highlights. Clinical Gastroenterology and Hepatology 2020;18:1405-8. [DOI: 10.1016/j.cgh.2020.04.021] [Reference Citation Analysis]
43 Eluri S, Iglesia EGA, Massaro M, Peery AF, Shaheen NJ, Dellon ES. Practice patterns and adherence to clinical guidelines for diagnosis and management of eosinophilic esophagitis among gastroenterologists. Dis Esophagus 2020:doaa025. [PMID: 32378700 DOI: 10.1093/dote/doaa025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
44 Greuter T, Straumann A. Medical algorithm: Diagnosis and treatment of eosinophilic esophagitis in adults. Allergy 2020;75:727-30. [PMID: 31714997 DOI: 10.1111/all.14112] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
45 Comer GM, Bush MA, Dellon ES, Marino MT. Effect of Food Intake and Body Position on the Pharmacokinetics of Swallowed APT-1011, a Fluticasone Orally Disintegrating Tablet, in Healthy Adult Volunteers. J Clin Pharmacol 2020;60:734-43. [PMID: 31943257 DOI: 10.1002/jcph.1572] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Schreiner P, Meissgeier S, Safroneeva E, Greuter T, Rogler G, Schoepfer A, Simon D, Simon HU, Biedermann L, Straumann A. Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2020;18:2456-62. [PMID: 31812655 DOI: 10.1016/j.cgh.2019.11.057] [Reference Citation Analysis]
47 Laquintana V, Asim MH, Lopedota A, Cutrignelli A, Lopalco A, Franco M, Bernkop-schnürch A, Denora N. Thiolated hydroxypropyl-β-cyclodextrin as mucoadhesive excipient for oral delivery of budesonide in liquid paediatric formulation. International Journal of Pharmaceutics 2019;572:118820. [DOI: 10.1016/j.ijpharm.2019.118820] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
48 Greuter T, Hirano I, Dellon ES. Emerging therapies for eosinophilic esophagitis. J Allergy Clin Immunol 2020;145:38-45. [PMID: 31705907 DOI: 10.1016/j.jaci.2019.10.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
49 Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, Gebhart JH, Galanko JA, Baron JA, Shaheen NJ. Rapid Recurrence of Eosinophilic Esophagitis Activity After Successful Treatment in the Observation Phase of a Randomized, Double-Blind, Double-Dummy Trial. Clin Gastroenterol Hepatol. 2020;18:1483-1492.e2. [PMID: 31499249 DOI: 10.1016/j.cgh.2019.08.050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
50 Sehmbhi M, Segal J. Highlights from the literature. Frontline Gastroenterol 2019;10:440-1. [DOI: 10.1136/flgastro-2019-101279] [Reference Citation Analysis]
51 de Rooij WE, Dellon ES, Parker CE, Feagan BG, Jairath V, Ma C, Bredenoord AJ. Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review. Drugs 2019;79:1419-34. [DOI: 10.1007/s40265-019-01173-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
52 Kavitt RT, Katzka DA. Six of One Steroid, Half a Dozen of the Other. Gastroenterology 2019;157:14-5. [PMID: 31150599 DOI: 10.1053/j.gastro.2019.05.043] [Reference Citation Analysis]